Blood cancers

Check point inhibitor trial grinds to a halt

The FDA has placed a partial hold on three clinical trials investigating nivolumab (Opdivo) based combination treatments in patients with relapsed or refractory multiple myeloma. The announcement follows a couple of months after the discontinuation of two trials of another checkpoint inhibitor pembrolizumab (Keytruda) combined with other treatments in patients with multiple myeloma. The FDA said ...

Already a member?

Login to keep reading.

© 2021 the limbic